| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13cf25eb1bef6199475314477618b46 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate |
2016-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_605084163314bbb6b078954c69d67c5c |
| publicationDate |
2017-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20170134462-A |
| titleOfInvention |
Treatment method combining mdm2 inhibitor and btk inhibitor |
| abstract |
A method for treating medicines / cancers comprising a combination of a compound having MDM2 inhibitory activity and a compound having BTK inhibitory activity. (3'R, 4'S, 5'R) -N - [(3R, 6S) -6-carbamoyltetrahydro-2H- -3-fluoropyridin-4-yl) -4,4-dimethyl-2 "-oxo-1", 2 "-dihydrodipyrro [cyclohexane-1,2'-pyrrolidin- "-Indole] -5'-carboxamide or a pharmaceutically acceptable salt thereof with ibrutinib or a pharmaceutically acceptable salt thereof. |
| priorityDate |
2015-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |